Ardelyx Inc
F:41X
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ardelyx Inc
F:41X
|
US |
|
Shoprite Holdings Ltd
OTC:SRHGF
|
ZA |
|
Kokuyo Co Ltd
TSE:7984
|
JP |
|
Engie SA
OTC:ENGQF
|
FR |
|
C
|
Celldex Therapeutics Inc
SWB:TCE2
|
US |
|
T
|
Tamburi Investment Partners SpA
F:T1I
|
IT |
|
P
|
Pultegroup Inc
SWB:PU7
|
US |
|
Dow Inc
LSE:0A1S
|
US |
|
C
|
Chipotle Mexican Grill Inc
XBER:C9F
|
US |
|
Tokyo Century Corp
OTC:TCNRF
|
JP |
|
R
|
Robert Walters PLC
XBER:RBW
|
UK |
|
CRH PLC
LSE:CRH
|
IE |
|
Bio-Techne Corp
NASDAQ:TECH
|
US |
|
U
|
Unicharm Corp
SWB:UN4
|
JP |
|
Brookfield Wealth Solutions Ltd
NYSE:BNT
|
BM |
|
H
|
Hermes International SCA
XBER:HMI
|
FR |
|
C
|
Coca-Cola Co
XMUN:CCC3
|
US |
|
Zillow Group Inc
NASDAQ:ZG
|
US |
|
M
|
Microstrategy Inc
F:MIGA
|
US |
|
E
|
Elica SpA
F:7L4
|
IT |
|
A
|
Abb Ltd
XBER:ABJA
|
CH |
|
Tokyo Electron Ltd
TSE:8035
|
JP |
|
C
|
CPI Card Group Inc
SWB:CPB1
|
US |
|
Liberty Media Corp
NASDAQ:FWONK
|
US |
Ardelyx Inc
Ardelyx is a biopharmaceutical company focused on medicines for gastrointestinal and kidney-related conditions. Its main products are prescription drugs that help treat problems like constipation from certain causes and help control phosphate levels in people with chronic kidney disease. The company does not sell consumer goods; it develops and commercializes specialized therapies for doctors to prescribe. The company makes money mainly by selling its approved drugs through pharmacies and healthcare channels, and by working with partners in markets where it has licensing or commercialization agreements. Its customers are patients, physicians, and healthcare systems that need treatment options for conditions that can be hard to manage with older medicines. What sets Ardelyx apart is its focus on small-molecule drugs for disease areas where the treatment choice has often been limited. Instead of trying to be a broad drug company, it concentrates on a few targeted medicines and on building medical acceptance for them in specialty care settings.
Ardelyx is a biopharmaceutical company focused on medicines for gastrointestinal and kidney-related conditions. Its main products are prescription drugs that help treat problems like constipation from certain causes and help control phosphate levels in people with chronic kidney disease. The company does not sell consumer goods; it develops and commercializes specialized therapies for doctors to prescribe.
The company makes money mainly by selling its approved drugs through pharmacies and healthcare channels, and by working with partners in markets where it has licensing or commercialization agreements. Its customers are patients, physicians, and healthcare systems that need treatment options for conditions that can be hard to manage with older medicines.
What sets Ardelyx apart is its focus on small-molecule drugs for disease areas where the treatment choice has often been limited. Instead of trying to be a broad drug company, it concentrates on a few targeted medicines and on building medical acceptance for them in specialty care settings.
Revenue growth: Ardelyx reported Q1 2026 total product revenue of $93.4 million, up 38% year over year, driven mainly by IBSRELA growth.
IBSRELA momentum: IBSRELA revenue rose 58% year over year to $70.1 million, and management said demand stayed strong despite normal seasonality and two severe winter storms.
XPHOZAH progress: XPHOZAH revenue was $23.3 million, with paid prescriptions up 19% year over year after adjusting for a prior-year return reserve benefit.
Guidance reaffirmed: The company reiterated full-year 2026 revenue guidance of $410 million to $430 million for IBSRELA and $110 million to $120 million for XPHOZAH.
Pipeline investment: Ardelyx said it is advancing the ACCEL Phase III CIC trial on schedule, with enrollment expected to finish by year-end and top-line data in the second half of 2027.
Financial strength: Cash was $238.1 million at quarter-end, and management said the recent debt refinancing extended maturity by 2 years and lowered the cost of capital.
